Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANIX Stock Forecast 2026-2027
$2.47
Current Price
$82.81M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ANIX Price Targets
+466.8%
To High Target of $14.00
+304.9%
To Median Target of $10.00
+264.4%
To Low Target of $9.00
ANIX Price Momentum
+0.4%
1 Week Change
-12.4%
1 Month Change
-26.0%
1 Year Change
-20.8%
Year-to-Date Change
-54.8%
From 52W High of $5.46
+6.5%
From 52W Low of $2.32
📊 TOP ANALYST CALLS
Did ANIX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Anixa is one of their latest high-conviction picks.
Latest ANIX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ANIX has a bullish consensus with a median price target of $10.00 (ranging from $9.00 to $14.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $2.47, the median forecast implies a 304.9% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANIX Analyst Ratings
3
Buy
0
Hold
0
Sell
ANIX Price Target Range
Low
$9.00
Average
$10.00
High
$14.00
Current: $2.47
Latest ANIX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANIX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 8, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $10.00 |
| Mar 31, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Feb 4, 2026 | D. Boral Capital | Buy | Maintains | $N/A | |
| Dec 12, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Oct 7, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 22, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Sep 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 9, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 19, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Aug 5, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jun 10, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| May 29, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Apr 10, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 26, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Mar 25, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 21, 2025 | Maxim Group | Buy | Initiates | $N/A | |
| Feb 18, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 22, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Jan 14, 2025 | D. Boral Capital | Buy | Maintains | $N/A | |
| Nov 19, 2024 | D. Boral Capital | Buy | Maintains | $N/A |
Anixa Biosciences Inc. (ANIX) Competitors
The following stocks are similar to Anixa based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ANIX
Anixa Biosciences
mkt cap
82.81M
Anixa Biosciences Inc. (ANIX) Financial Data
Anixa Biosciences Inc. has a market capitalization of $82.81M with a P/E ratio of -7.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -72.0%.
Valuation Metrics
Market Cap
$82.81M
Enterprise Value
$65.20M
P/E Ratio
-7.2x
PEG Ratio
0.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+16.3%
Current Ratio
9.8x
Debt/Equity
1.4x
ROE
-72.0%
ROA
-41.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Anixa Biosciences Inc. (ANIX) Business Model
About Anixa Biosciences Inc.
What They Do
Develops cancer therapies and vaccines.
Business Model
Anixa Biosciences Inc. operates as a clinical-stage biotechnology company, generating potential revenue through the development and commercialization of innovative cancer therapies and vaccines. The company focuses on CAR-T therapies and preventive vaccines, aiming to meet significant unmet medical needs in oncology, particularly for challenging cancers like ovarian and triple negative breast cancer.
Additional Information
Founded in 1982 and based in San Jose, California, Anixa is advancing its pipeline through clinical trials and expanding its intellectual property. The company is positioned in the fast-evolving immuno-oncology sector, which presents high growth potential and investment opportunities.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
5
CEO
Dr. Amit Kumar Ph.D.
Country
United States
IPO Year
1983
Website
www.anixa.comAnixa Biosciences Inc. (ANIX) Latest News & Analysis
Latest News
Quick Summary
Anixa Biosciences will present positive Phase 1 trial results for its ovarian cancer CAR-T therapy and breast cancer vaccine at a symposium on June 22-23, 2026, showcasing clinical progress.
Why It Matters
Positive clinical trial results for Anixa's CAR-T therapy and breast cancer vaccine can indicate potential revenue growth, attracting investor interest and impacting stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Anixa Biosciences received a Notice of Allowance from the Canadian Intellectual Property Office for a patent related to its ovarian cancer vaccine technology.
Why It Matters
The patent allowance for Anixa's ovarian cancer vaccine could enhance its market position, attract investment, and drive potential revenue growth, signaling a positive outlook for the company's future.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Anixa Biosciences reported positive survival outcomes in its Phase 1 trial of lira-cel for recurrent ovarian cancer, with patients surviving beyond expected median survival times.
Why It Matters
Positive survival data from Anixa's lira-cel trial suggests potential for significant breakthroughs in treating ovarian cancer, which could drive stock value and investor interest in the biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology
1 month ago
Quick Summary
Anixa Biosciences has secured a patent in Mexico for its breast cancer vaccine, extending intellectual property protection until 2040, enhancing its market position in regions with high breast cancer rates.
Why It Matters
Expanded patent protection in Mexico enhances Anixa Biosciences' market position and potential revenue from its breast cancer vaccine, signaling growth prospects and innovation in oncology.
Source: PRNewsWire
Market Sentiment:
Neutral
Anixa Biosciences Interview to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
1 month ago
Quick Summary
Anixa Biosciences (NASDAQ: ANIX) will feature an interview with CEO Dr. Amit Kumar on Bloomberg TV's RedChip show on May 2 at 7pm ET, focusing on cancer treatment and prevention.
Why It Matters
Anixa's CEO interview on Bloomberg TV could enhance visibility and investor interest, potentially impacting stock performance and market perception of the company.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Anixa Biosciences announced positive survival data for lira-cel in its Phase 1 trial. Cheryl Cox will present at the ISCT 2026 Annual Meeting in Dublin from May 6-9, 2026.
Why It Matters
Positive survival data from lira-cel boosts Anixa's credibility and potential for successful cancer treatment, likely enhancing investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ANIX Stock
What is Anixa Biosciences Inc.'s (ANIX) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Anixa Biosciences Inc. (ANIX) has a median price target of $10.00. The highest price target is $14.00 and the lowest is $9.00.
Is ANIX stock a good investment in 2026?
According to current analyst ratings, ANIX has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.47. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANIX stock?
Wall Street analysts predict ANIX stock could reach $10.00 in the next 12 months. This represents a 304.9% increase from the current price of $2.47. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Anixa Biosciences Inc.'s business model?
Anixa Biosciences Inc. operates as a clinical-stage biotechnology company, generating potential revenue through the development and commercialization of innovative cancer therapies and vaccines. The company focuses on CAR-T therapies and preventive vaccines, aiming to meet significant unmet medical needs in oncology, particularly for challenging cancers like ovarian and triple negative breast cancer.
What is the highest forecasted price for ANIX Anixa Biosciences Inc.?
The highest price target for ANIX is $14.00 from at , which represents a 466.8% increase from the current price of $2.47.
What is the lowest forecasted price for ANIX Anixa Biosciences Inc.?
The lowest price target for ANIX is $9.00 from at , which represents a 264.4% increase from the current price of $2.47.
What is the overall ANIX consensus from analysts for Anixa Biosciences Inc.?
The overall analyst consensus for ANIX is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are ANIX stock price projections?
Stock price projections, including those for Anixa Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 14, 2026 9:18 PM UTC